DSC Advisors’s Neos Therapeutics, Inc NEOS Stock Holding History

DSC Advisors’s Portfolio NEOS Stock Details NEOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-31,240	Closed	-$656K	–	78
2015 Q3	$656K	Buy	+31,240	New	+$688K	0.32%	47

Other funds holding NEOS

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

DSC Advisors's NEOS Position: Q2 2018 in Review

DSC Advisors sold out of Neos Therapeutics, Inc (NEOS) in Q2 2018, closing a stake of 330,576 shares — an estimated $2.74M sold.

DSC Advisors first reported a position in NEOS in Q3 2015 and held it in 11 quarters. The position peaked at $17.2M in Q3 2015. 73 funds tracked by Wall St. Rank hold NEOS as of Q2 2018.

DSC Advisors reported no remaining Neos Therapeutics, Inc position as of Q2 2018 after selling out during the quarter.
DSC Advisors sold 330,576 Neos Therapeutics, Inc shares in Q2 2018, an estimated $2.74M.
DSC Advisors first reported a position in Neos Therapeutics, Inc in Q3 2015 and held it in 11 quarters.
DSC Advisors's Neos Therapeutics, Inc position peaked at $17.2M in Q3 2015.
73 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q2 2018.

Based on DSC Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.